Andrey M. Semenov

Moscow, MOW, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Fortelyzin in the treatment of acute ischemic stroke in patients ≥80 years old: data from the observational study FORPI registry

Fortelyzin in the treatment of acute ischemic stroke in patients ≥80 years old: data from the observational study FORPI registry

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: April 15, 2026

Fortelizin in bridging therapy of acute ischemic stroke: data from the observational study FORPI registry

Fortelizin in bridging therapy of acute ischemic stroke: data from the observational study FORPI registry

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: March 05, 2026

Fortelyzin for acute ischaemic stroke treatment in an extended (4.5 to 24 hours from the onset of symptoms) time window: data from the observational study FORPI registry

Fortelyzin for acute ischaemic stroke treatment in an extended (4.5 to 24 hours from the onset of symptoms) time window: data from the observational study FORPI registry

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: February 09, 2026

Fortelyzin for acute ischaemic stroke treatment: an open, prospective, non-interventional, observational study FORPI registry

Fortelyzin for acute ischaemic stroke treatment: an open, prospective, non-interventional, observational study FORPI registry

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: January 12, 2026

Thrombolysis With the Non-Immunogenic Staphylokinase for Acute Ischemic Stroke in the FORPI Registry: An Observational Study.

Thrombolysis With the Non-Immunogenic Staphylokinase for Acute Ischemic Stroke in the FORPI Registry: An Observational Study.

Journal: Stroke

Published: November 26, 2025

Prognostic outcome of intravenous thrombolysis with non-immunogenic staphylokinase in patients aged ≥ 60 years with acute ischemic stroke by THRIVE scale.

Prognostic outcome of intravenous thrombolysis with non-immunogenic staphylokinase in patients aged ≥ 60 years with acute ischemic stroke by THRIVE scale.

Journal: Journal of thrombosis and thrombolysis

Published: December 26, 2024

Intraarterial intrathrombus thrombolysis with non-immunogenic staphylokinase vs surgery in patients with acute limb ischemia: protocol of a multicenter, open-label, randomized clinical trial FORAT

Intraarterial intrathrombus thrombolysis with non-immunogenic staphylokinase vs surgery in patients with acute limb ischemia: protocol of a multicenter, open-label, randomized clinical trial FORAT

Journal: Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery

Published: October 08, 2024

The Safety of Non-immunogenic Recombinant Staphylokinase in Elderly Patients With Massive Pulmonary Embolism: A Randomized Clinical Trial FORPE.

The Safety of Non-immunogenic Recombinant Staphylokinase in Elderly Patients With Massive Pulmonary Embolism: A Randomized Clinical Trial FORPE.

Journal: Health science reports

Published: October 04, 2024

Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy.

Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy.

Journal: European urology

Published: August 30, 2024

Non-immunogenic recombinant staphylokinase versus alteplase for patients with massive pulmonary embolism: a randomized open-label, multicenter, parallel-group, non-inferiority trial, FORPE.

Non-immunogenic recombinant staphylokinase versus alteplase for patients with massive pulmonary embolism: a randomized open-label, multicenter, parallel-group, non-inferiority trial, FORPE.

Journal: Journal of thrombosis and haemostasis : JTH

Published: June 17, 2024

Catalytic Decomposition of H2O2 in the Aqueous Dispersions of the Potassium Polytitanates Produced in Different Conditions of Molten Salt Synthesis.

Catalytic Decomposition of H2O2 in the Aqueous Dispersions of the Potassium Polytitanates Produced in Different Conditions of Molten Salt Synthesis.

Journal: Molecules (Basel, Switzerland)

Published: May 30, 2023

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302).

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302).

Journal: BMC cancer

Published: August 05, 2022

Showing 1-12 of 23

Last Updated: 09/26/2026